Insmed Target of Unusually High Options Trading (NASDAQ:INSM)

Insmed Incorporated (NASDAQ:INSM - Get Free Report) saw unusually large options trading on Friday. Traders purchased 20,174 call options on the stock. This represents an increase of 1,592% compared to the typical volume of 1,192 call options.

Insmed Trading Down 1.6 %

Shares of Insmed stock traded down $0.41 on Friday, reaching $25.97. 2,922,713 shares of the company were exchanged, compared to its average volume of 1,763,194. Insmed has a one year low of $18.08 and a one year high of $32.00. The company has a market capitalization of $3.86 billion, a price-to-earnings ratio of -4.81 and a beta of 0.93. The company has a 50-day moving average of $26.59 and a 200 day moving average of $27.07.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.22) by $0.16. The company had revenue of $75.50 million for the quarter, compared to the consensus estimate of $77.76 million. During the same quarter in the prior year, the company earned ($1.17) EPS. The company's revenue for the quarter was up 15.8% on a year-over-year basis. Analysts predict that Insmed will post -4.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Insmed by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 14,509,235 shares of the biopharmaceutical company's stock worth $393,636,000 after acquiring an additional 383,714 shares during the last quarter. Loomis Sayles & Co. L P increased its holdings in shares of Insmed by 47.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 2,383,039 shares of the biopharmaceutical company's stock worth $60,172,000 after acquiring an additional 769,443 shares during the last quarter. RTW Investments LP increased its holdings in shares of Insmed by 86.5% during the 3rd quarter. RTW Investments LP now owns 1,865,108 shares of the biopharmaceutical company's stock worth $47,094,000 after acquiring an additional 865,108 shares during the last quarter. Norges Bank acquired a new position in shares of Insmed during the 4th quarter worth approximately $45,029,000. Finally, Principal Financial Group Inc. increased its holdings in shares of Insmed by 5.9% during the 1st quarter. Principal Financial Group Inc. now owns 1,439,280 shares of the biopharmaceutical company's stock worth $39,048,000 after acquiring an additional 79,717 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on INSM. Barclays boosted their target price on Insmed from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Thursday, April 11th. Guggenheim lifted their price objective on Insmed from $52.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, February 27th. Wolfe Research began coverage on Insmed in a report on Thursday, February 15th. They set an "outperform" rating and a $42.00 price objective on the stock. StockNews.com cut Insmed from a "hold" rating to a "sell" rating in a report on Monday. Finally, Truist Financial began coverage on Insmed in a report on Tuesday, April 23rd. They set a "buy" rating and a $48.00 price objective on the stock. One research analyst has rated the stock with a sell rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and an average target price of $45.08.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.